FLT3-ITD Mutation
Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model
... AML, FLT3/ITD mutation is a rare event in human T-ALLs, with an incidence of 2% or less and no prognostic ...While Flt3 is virtually unexpressed in T-ALL derived from our double mutant mice, ...
12
Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia
... CEBPA mutation are considered to be the favorable prognostic risk stratification for AML, whereas high allele burden of FLT3-ITD mutation with or without mutant NPM1 is classified as ...
14
Biological and clinical influences of <em>NPM1 </em>in acute myeloid leukemia patients with <em>DNMT3A</em> mutations
... age and PB blast percentage were 76 and 36%, respectively, and ranged from 32 to 100% and 0 to 97%; there were 30 (58.8%) cases with BM blasts ≥ 70% and six (30.0%) cases with PB blasts ≥ 70%. In 28 of the 51 patients ...
9
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
... of FLT3-ITD mutation, improving the knowledge of this AML subgroup pathophysiology appears as an essential task for the next ...by FLT3- ITD have been identified, but downstream ...
18
Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia
... and FLT3-ITD mutation ad- versely affected OS with statistical significance (P = ...that FLT3-ITD, FLT3-TKD and MN1 mutations adversely af- fected ...NPM1 mutation showed ...
15
Chronic FLT3-ITD Signaling in Acute Myeloid Leukemia Is Connected to a Specific Chromatin Signature
... the FLT3 transmembrane domain as a paradigm. FLT3-ITD mutations are found in 25% of KN-AML and lead to constitutive activation of the downstream mitogen-activated protein kinase (MAPK), AKT, and ...
17
FLT3-ITD Negative Refractory/Relapsed or Geratic AML Patients Responded Well to Salvage Treatment with Low Dose Cytarabine and Sorafenib
... without FLT3-ITD mutation, there are obvious shortcomings in this ...c-Kit mutation and sorafenib responses in our R/R patients still needs further study, because c-Kit mutation also ...
6
Cytogenetic and FMS-Like Tyrosine Kinase 3 Mutation Analyses in Acute Promyelocytic Leukemia Patients
... and mutation of FLT3 (FMS-like tyrosine kinase 3) tyrosine kinase receptor are the frequent genetic alterations in acute myeloid ...of FLT3 mutations in acute promyelocytic leukemia (APL) is not ...
8
oa Molecular Diagnosis and Vaccines - Prognostic significance of activating FLT3 mutations in adults with acute myeloid leukemia
... for FLT3- ITD mutation, 14F ( 5’-GCA ATT TAG GTA TGA AAG CCA GC-3’) and 15R (5’-CTT TCA GCA TTT TGA CGG CAA CC-3’) as described previously, (Sheikhha et ...
13
<p>Acute myeloid leukemia patient with <em>FLT3-ITD</em> and <em>NPM1</em> double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis </p>
... of FLT3 mutation, internal tandem duplication of FLT3 (FLT3-ITD) and tyrosine kinase domain of FLT3 ...(FLT3-TKD). FLT3- ITD is the major type and reported ...
14
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3 -ITD mutated acute myeloid leukemia
... with FLT3- ITD achieve a transient remission, they often suffer early relapse with emergence of treatment resistance ...Several FLT3 inhibitors (sorafenib, midostaurin (PKC-412), quizartinib (AC220), ...
16
Molecular characteristics and chromatin texture features in acute promyelocytic leukemia
... with FLT3-ITD presented a microgranular morphology, PB leukocytosis and expression of HLA-DR, CD34 and ...count, FLT3-ITD mutation, microgranular morphology, methylation of CDKN2B, ...
8
An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia
... the FLT3-ITD oncogenic receptor, we screened a library of siRNAs targeting the entire human kinome (Supplementary Table ...a FLT3-ITD mutation- were used to probe for cell ...specific ...
11
<p>Long Noncoding RNA SOCS2-AS Promotes Leukemogenesis in FLT3-ITD+ Acute Myeloid Leukemia Through miRNA-221</p>
... in FLT3-ITD+ patients and cell lines (Molm-13 and ...in FLT3-ITD+ (n=71) and FLT3-ITD- (n=287) patients compared to healthy controls (n=330) ...in FLT3-ITD+ (n=71) ...
10
Frequency of FLT3 ITD and FLT3 TKD Mutations in Multiple Myeloma Patients (A Case Control Study)
... FLT3 mutation has been proved as a determining factor in some hematologic malignancies, and its evaluation may guide proper treatment ...no FLT3 mutation either TKD or ITD was found in ...
7
SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells
... of FLT3 by using a protein substrate ...on FLT3 and its FLT3D835Y and FLT3 D835H mutant forms (data not ...type FLT3 with an IC 50 value of ...
6
Reindl, Carola (2007): Aberrante Aktivierung der Rezeptortyrosinkinase FLT3 in der akuten myeloischen Leukämie. Dissertation, LMU München: Medizinische Fakultät
... 1997). FLT3 wird aufgrund einer sterischen Hinderung durch ein nicht- konserviertes Phenylalanin (F691) nicht inhibiert (Bohmer, ...auch FLT3 hemmt. Eine Phase-II-Studie mit AML-Patienten, die eine ...
129
Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia
... The migration capacity can be related to cell mechanics. Very recently, we introduced RT-DC, which allows on-the-fly analysis of deformed cell shape [29]. Using this technology, we provide evidence for decreased ...
12
<p>Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date</p>
... Due to the QTc prolongation issues and cytopenias, a second randomized phase 2b trial was done to evaluate lower doses of quizartinib. Patients >18 years of age with either relapse after allogeneic transplant or ...
13
The new perspectives of targeted therapy in acute myeloid leukemia
... The greatest benefits were observed in a group of patients who did not qualify for SCT previously untreated with FLT3 inhibitors. A promising effect was achieved in pre- clinical trials by a combination of ATRA ...
6